Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
TIL Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Instil Bio, Inc.NASDAQ: TIL
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $5.35M fell 41.3% year over year, in line with the -41.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 11.7% from the prior quarter. Over 3 fiscal years it compounded at -24.1% a year.
Context
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -38.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.35M-11.7% QoQ
- Last fiscal yearDec 2025
- $27.22M-38.4% YoY
- LTMMar 2026
- $23.46M-41.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -41.3% | -100.0% | -58.7 pp |
| 1 year | -38.4% | -100.0% | -61.6 pp |
| 3-year CAGR | -24.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 27.22M USD
- Year-over-year change
- -38.4%
- 4-year CAGR
- -14.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.22M | -38.4% |
| FY2024 | 2024-12-31 | 44.21M | -7.0% |
| FY2023 | 2023-12-31 | 47.55M | -23.6% |
| FY2022 | 2022-12-31 | 62.24M | +21.3% |
| FY2021 | 2021-12-31 | 51.31M | — |
Selling, General & Admin vs competitors
How TIL compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -41.6% is the 8th highest of 9, against a peer median of -27.8%.
- Over three fiscal years its annual growth of -24.1% compares with a peer median of -5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $39.91M USD | -32.7% | +5.7% | — | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $34.97M USD | -57.3% | -11.6% | — | |
| LTM Mar 2026 | $23.46M USD | -41.6% | -24.1% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $23.29M USD | -40.2% | -9.5% | — |
| LTM Mar 2026 | CA$18.6M CAD | +58.0% | +35.4% | — | |
| LTM Mar 2026 | $18.36M USD | +21.1% | -6.5% | 244.9% | |
| LTM Mar 2026 | $17.37M USD | -6.9% | -4.3% | 1736.5% | |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| Peer median (excluding TIL) | — | -27.8% | -5.4% | 990.7% | |
Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 5.99M | 0 | 0 | 534K |
| Gross Profit | 0 | (5.99M) | 0 | 0 | (534K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 107.25M | 141.06M | 39.6M | 11.84M | 10M |
| Selling, General & Admin | 51.31M | 62.24M | 47.55M | 44.21M | 27.22M |
| Operating Expenses | 155.56M | 200.18M | 159.17M | 73.54M | 52.37M |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| EBITDA | (152.51M) | (217.38M) | (147.12M) | (62.53M) | (65.01M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (155.56M) | (206.17M) | (159.17M) | (73.54M) | (52.91M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 80K | 3.66M | 8.87M | 6.99M | 3.86M |
| Interest Expense | 0 | 1.88M | 5.21M | 8.99M | 5.83M |
| Other Income / Expenses | (1.2M) | (19.08M) | 3.08M | (594K) | (18.47M) |
| Income Before Tax | (156.76M) | (225.25M) | (156.09M) | (74.14M) | (71.37M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39K | (2.07M) | 0 | 0 | 0 |
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| EPS (Diluted) | (29.60) | (34.46) | (24.00) | (11.39) | (10.70) |
| Weighted Avg Shares | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M |
| Weighted Avg Shares (Diluted) | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M |
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.